Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

Positive

AI Analysis

Summary

Novartis has agreed to acquire Myricx Bio, a UK-based biotech company developing next-generation antibody-drug conjugates with novel NMTi payloads for cancer treatment. The acquisition expands Novartis's ADC pipeline and cancer therapeutic options.

Outcome Details

Agreement entered into for acquisition

Importance:7/10

Sentiment:

0.70

M&Aantibody-drug conjugatesoncologypayload technology

Related Companies

$NVS

Read the original article

Published by GlobeNewswire Pharma on July 6, 2026 5:00 AM

Read Original